Ionis Pharmaceuticals, Inc. (IONS) Set to Announce Earnings on Tuesday
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) will be posting its quarterly earnings results before the market opens on Tuesday, November 7th. Analysts expect Ionis Pharmaceuticals to post earnings of ($0.06) per share for the quarter.
Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings results on Tuesday, August 8th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.03). The business had revenue of $104.15 million during the quarter, compared to analysts’ expectations of $93.29 million. Ionis Pharmaceuticals had a net margin of 5.25% and a return on equity of 15.52%. The firm’s quarterly revenue was up 170.7% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.47) EPS. On average, analysts expect Ionis Pharmaceuticals to post $-0.13 EPS for the current fiscal year and $-0.27 EPS for the next fiscal year.
Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) opened at 58.31 on Tuesday. The firm has a 50-day moving average price of $56.67 and a 200 day moving average price of $51.42. The stock has a market cap of $7.25 billion, a PE ratio of 280.34 and a beta of 3.12. Ionis Pharmaceuticals, Inc. has a 12-month low of $24.58 and a 12-month high of $65.51.
In other Ionis Pharmaceuticals news, SVP C Frank Bennett sold 12,250 shares of the firm’s stock in a transaction that occurred on Wednesday, October 18th. The stock was sold at an average price of $65.00, for a total value of $796,250.00. Following the completion of the sale, the senior vice president now owns 27,291 shares in the company, valued at approximately $1,773,915. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Patrick R. O’neil sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $55.00, for a total value of $55,000.00. Following the completion of the sale, the senior vice president now owns 10,633 shares of the company’s stock, valued at approximately $584,815. The disclosure for this sale can be found here. Insiders sold a total of 97,636 shares of company stock valued at $5,665,565 in the last quarter. Corporate insiders own 2.13% of the company’s stock.
An institutional investor recently raised its position in Ionis Pharmaceuticals stock. The Manufacturers Life Insurance Company grew its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 9.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,744 shares of the company’s stock after acquiring an additional 311 shares during the quarter. The Manufacturers Life Insurance Company ‘s holdings in Ionis Pharmaceuticals were worth $190,000 as of its most recent SEC filing. Institutional investors and hedge funds own 89.01% of the company’s stock.
A number of brokerages have recently commented on IONS. Stifel Nicolaus increased their price objective on Ionis Pharmaceuticals from $42.00 to $50.00 and gave the company a “hold” rating in a report on Wednesday, August 9th. TheStreet raised Ionis Pharmaceuticals from a “d+” rating to a “c-” rating in a report on Wednesday, July 5th. Needham & Company LLC reissued a “buy” rating and set a $64.00 price objective on shares of Ionis Pharmaceuticals in a report on Wednesday, July 26th. Zacks Investment Research lowered Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, August 8th. Finally, Evercore ISI began coverage on Ionis Pharmaceuticals in a report on Wednesday, August 16th. They set an “outperform” rating and a $65.00 price objective on the stock. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Ionis Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $49.64.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.